• Return to Headlines

Uptrend Call Working As Nektar Therapeutics Stock Rises 16.2% (NKTR)

By Shiri Gupta

SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 3 months, Nektar Therapeutics has returned 16.23% as of today's recent price of $13.75.

In the past 52 weeks, Nektar Therapeutics share prices have been bracketed by a low of $8.72 and a high of $14.47 and are now at $13.75, 58% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.6% while the 200-day MA has risen 0.3%.

Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any shifts in the trajectory of Nektar Therapeutics shares.

Log in and add Nektar Therapeutics (NKTR) to your watchlist today so you can receive a real-time alert when the shares are about to change trend.

Keywords: spotlights nektar therapeutics

Ticker(s): NKTR